Maintenance Notice

Due to necessary scheduled maintenance, the JMIR Publications website will be unavailable from Wednesday, July 01, 2020 at 8:00 PM to 10:00 PM EST. We apologize in advance for any inconvenience this may cause you.

Who will be affected?

Accepted for/Published in: JMIR Dermatology

Date Submitted: Dec 26, 2022
Date Accepted: Jul 23, 2023
Date Submitted to PubMed: Aug 26, 2023

The final, peer-reviewed published version of this preprint can be found here:

Isotretinoin Use in Transmasculine Patients and Its Implication on Chest Masculinization Surgery: Scoping Review of the Literature

Strock D, Sivesind TE, Dellavalle RP, Mundinger GS

Isotretinoin Use in Transmasculine Patients and Its Implication on Chest Masculinization Surgery: Scoping Review of the Literature

JMIR Dermatol 2023;6:e45351

DOI: 10.2196/45351

PMID: 37616418

PMCID: 10450534

Warning: This is an author submission that is not peer-reviewed or edited. Preprints - unless they show as "accepted" - should not be relied on to guide clinical practice or health-related behavior and should not be reported in news media as established information.

Isotretinoin Use in Transmen and its Implication on Chest Masculinization Surgery: A Scoping Review of the Literature

  • Daniel Strock; 
  • Torunn E. Sivesind; 
  • Robert P. Dellavalle; 
  • Gerhard S. Mundinger

ABSTRACT

Background:

Acne often worsens in transmen on prolonged testosterone therapy. Isotretinoin is an oral retinoid used in the treatment of severe or refractory cases of acne, though it has been previously reported to cause hypertrophic scarring in patients undergoing some surgical procedures. Transmen may potentially be prescribed treatment for acne with isotretinoin while also planning to undergo chest masculinization surgery.

Objective:

To determine whether isotretinoin has a negative impact on post-operative healing in transmen undergoing chest masculinization surgery.

Methods:

A scoping review was performed using the PubMed database.

Results:

Acne tends to peak in transmen six months after initiation of testosterone treatment. Severe cases can be treated with isotretinoin, but may recur once treatment is discontinued, given ongoing hormone therapy. There is little to no evidence in the medical literature regarding peri-operative use of isotretinoin in transmen undergoing chest masculinization surgery specifically. In general, however, recent studies have found no evidence of increased hypertrophic scars or keloids in patients taking isotretinoin.

Conclusions:

Further studies are required to strengthen the current evidence that suggests that isotretinoin does not need to be discontinued before or after incisional or excisional surgeries, including chest masculinization surgery in transmen.


 Citation

Please cite as:

Strock D, Sivesind TE, Dellavalle RP, Mundinger GS

Isotretinoin Use in Transmasculine Patients and Its Implication on Chest Masculinization Surgery: Scoping Review of the Literature

JMIR Dermatol 2023;6:e45351

DOI: 10.2196/45351

PMID: 37616418

PMCID: 10450534

Download PDF


Request queued. Please wait while the file is being generated. It may take some time.

© The authors. All rights reserved. This is a privileged document currently under peer-review/community review (or an accepted/rejected manuscript). Authors have provided JMIR Publications with an exclusive license to publish this preprint on it's website for review and ahead-of-print citation purposes only. While the final peer-reviewed paper may be licensed under a cc-by license on publication, at this stage authors and publisher expressively prohibit redistribution of this draft paper other than for review purposes.